Effect of Rosiglitazone on N-nitroso-N-methylurea-induced Mammary Tumors in Rat
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
PubMed 2006 May-Jun;26(3A):2113-22
Abstract
Description
Fil: Bergoc, Rosa. Instituto Universitario de Ciencias de la Salud. Fundación Barceló; Argentina.
The objective of this study was to evaluate the in vivo antitumor action of rosiglitazone (Rosi) alone or in combination with tamoxifen (Tam) on experimental mammary tumors induced by N-nitroso-N-methylurea (NMU) in Sprague-Dawley rats. Animals bearing mammary tumors were treated with 0.06 mg/kg/day or 0.12 mg/kg/day of Rosi orally, 1 mg/kg/day of Tam sc, or with the combined treatment (Rosi+Tam). After 25 days of treatments, the following responses were observed: 45% of tumors were responsive to 0.06 mg/kg/day of Rosi treatment, while 55% of tumors under Tam treatment responded. Results of the combined Rosi+Tam treatment indicate that 75% of tumors were responsive. Similar results were obtained with 0.12 mg/kg/day of Rosi. Apoptosis, necrosis and glandular hypersecretion were observed in Rosi-treated tumors. In all cases, the combined Rosi+Tam treatment potentiates the antitumor effect of Tam alone. No side-effect was observed after treatment at any assayed dose.
The objective of this study was to evaluate the in vivo antitumor action of rosiglitazone (Rosi) alone or in combination with tamoxifen (Tam) on experimental mammary tumors induced by N-nitroso-N-methylurea (NMU) in Sprague-Dawley rats. Animals bearing mammary tumors were treated with 0.06 mg/kg/day or 0.12 mg/kg/day of Rosi orally, 1 mg/kg/day of Tam sc, or with the combined treatment (Rosi+Tam). After 25 days of treatments, the following responses were observed: 45% of tumors were responsive to 0.06 mg/kg/day of Rosi treatment, while 55% of tumors under Tam treatment responded. Results of the combined Rosi+Tam treatment indicate that 75% of tumors were responsive. Similar results were obtained with 0.12 mg/kg/day of Rosi. Apoptosis, necrosis and glandular hypersecretion were observed in Rosi-treated tumors. In all cases, the combined Rosi+Tam treatment potentiates the antitumor effect of Tam alone. No side-effect was observed after treatment at any assayed dose.
Keywords
ARTICULO, MEDICINA, CANCER DE MAMA, FARMACOLOGIA